Baidu
map

Int J Biometeorol:PM2.5与过敏性鼻炎日门诊量相关性研究

2019-12-11 AlexYang MedSci原创

关于颗粒性物质PM2.5与过敏性鼻炎(AR)患者就诊数之间的相关性证据有限,尤其是在空气污染极度严重的国家中。最近,有研究人员阐释了中国北京居民中,PM2.5与AR日门诊量之间的相关性。研究总共包括了229685次AR就诊。在2010年1月1日到2012年6月30日之间每天的PM2.5浓度均值为99.5 (75.3) μg/m3。研究人员发现,PM2.5每增加10μg/m3,AR患者的就诊数量就会

关于颗粒性物质PM2.5与过敏性鼻炎(AR)患者就诊数之间的相关性证据有限,尤其是在空气污染极度严重的国家中。最近,有研究人员阐释了中国北京居民中,PM2.5与AR日门诊量之间的相关性。

研究总共包括了229685次AR就诊。在2010年1月1日到2012年6月30日之间每天的PM2.5浓度均值为99.5 (75.3) μg/m3。研究人员发现,PM2.5每增加10μg/m3,AR患者的就诊数量就会增加0.47%(95% CI: 0.39%到0.55%)。更多的是,亚群分析结果表明了上述相关性在不同的年龄(<65岁和≥65岁)组和性别中具有一致的显著性。然而,他们的研究在秋季时没有发现统计学显著相关性,但是在春季和夏季发现了显著的正相关关系(p<0.001)。

最后,研究人员指出,他们的研究表明了PM2.5与AR就诊之间的相关性情况,上述结果有助于现实生活中严重空气污染情况下,进一步的研究PM2.5以及其对疾病影响的情况。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645820, encodeId=06d9164582018, content=<a href='/topic/show?id=1c459e14547' target=_blank style='color:#2F92EE;'>#门诊量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97145, encryptionId=1c459e14547, topicName=门诊量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7823230852, createdName=lishiwen, createdTime=Thu Nov 05 22:44:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896588, encodeId=8b7f1896588a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jan 09 08:44:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837765, encodeId=c41e183e76510, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Apr 26 22:44:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047194, encodeId=840d204e19403, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 31 16:44:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918952, encodeId=c81719189526b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 28 22:44:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265014, encodeId=462b126501499, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Fri Dec 13 03:44:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376826, encodeId=bf6d3e68267b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 11 14:28:14 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645820, encodeId=06d9164582018, content=<a href='/topic/show?id=1c459e14547' target=_blank style='color:#2F92EE;'>#门诊量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97145, encryptionId=1c459e14547, topicName=门诊量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7823230852, createdName=lishiwen, createdTime=Thu Nov 05 22:44:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896588, encodeId=8b7f1896588a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jan 09 08:44:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837765, encodeId=c41e183e76510, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Apr 26 22:44:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047194, encodeId=840d204e19403, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 31 16:44:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918952, encodeId=c81719189526b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 28 22:44:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265014, encodeId=462b126501499, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Fri Dec 13 03:44:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376826, encodeId=bf6d3e68267b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 11 14:28:14 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
    2020-01-09 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1645820, encodeId=06d9164582018, content=<a href='/topic/show?id=1c459e14547' target=_blank style='color:#2F92EE;'>#门诊量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97145, encryptionId=1c459e14547, topicName=门诊量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7823230852, createdName=lishiwen, createdTime=Thu Nov 05 22:44:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896588, encodeId=8b7f1896588a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jan 09 08:44:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837765, encodeId=c41e183e76510, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Apr 26 22:44:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047194, encodeId=840d204e19403, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 31 16:44:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918952, encodeId=c81719189526b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 28 22:44:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265014, encodeId=462b126501499, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Fri Dec 13 03:44:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376826, encodeId=bf6d3e68267b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 11 14:28:14 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1645820, encodeId=06d9164582018, content=<a href='/topic/show?id=1c459e14547' target=_blank style='color:#2F92EE;'>#门诊量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97145, encryptionId=1c459e14547, topicName=门诊量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7823230852, createdName=lishiwen, createdTime=Thu Nov 05 22:44:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896588, encodeId=8b7f1896588a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jan 09 08:44:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837765, encodeId=c41e183e76510, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Apr 26 22:44:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047194, encodeId=840d204e19403, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 31 16:44:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918952, encodeId=c81719189526b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 28 22:44:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265014, encodeId=462b126501499, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Fri Dec 13 03:44:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376826, encodeId=bf6d3e68267b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 11 14:28:14 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1645820, encodeId=06d9164582018, content=<a href='/topic/show?id=1c459e14547' target=_blank style='color:#2F92EE;'>#门诊量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97145, encryptionId=1c459e14547, topicName=门诊量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7823230852, createdName=lishiwen, createdTime=Thu Nov 05 22:44:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896588, encodeId=8b7f1896588a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jan 09 08:44:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837765, encodeId=c41e183e76510, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Apr 26 22:44:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047194, encodeId=840d204e19403, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 31 16:44:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918952, encodeId=c81719189526b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 28 22:44:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265014, encodeId=462b126501499, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Fri Dec 13 03:44:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376826, encodeId=bf6d3e68267b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 11 14:28:14 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
    2020-08-28 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1645820, encodeId=06d9164582018, content=<a href='/topic/show?id=1c459e14547' target=_blank style='color:#2F92EE;'>#门诊量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97145, encryptionId=1c459e14547, topicName=门诊量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7823230852, createdName=lishiwen, createdTime=Thu Nov 05 22:44:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896588, encodeId=8b7f1896588a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jan 09 08:44:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837765, encodeId=c41e183e76510, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Apr 26 22:44:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047194, encodeId=840d204e19403, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 31 16:44:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918952, encodeId=c81719189526b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 28 22:44:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265014, encodeId=462b126501499, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Fri Dec 13 03:44:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376826, encodeId=bf6d3e68267b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 11 14:28:14 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1645820, encodeId=06d9164582018, content=<a href='/topic/show?id=1c459e14547' target=_blank style='color:#2F92EE;'>#门诊量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97145, encryptionId=1c459e14547, topicName=门诊量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da7823230852, createdName=lishiwen, createdTime=Thu Nov 05 22:44:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896588, encodeId=8b7f1896588a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Jan 09 08:44:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837765, encodeId=c41e183e76510, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Apr 26 22:44:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047194, encodeId=840d204e19403, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Dec 31 16:44:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918952, encodeId=c81719189526b, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 28 22:44:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265014, encodeId=462b126501499, content=<a href='/topic/show?id=9574144034a' target=_blank style='color:#2F92EE;'>#PM2.5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14403, encryptionId=9574144034a, topicName=PM2.5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Fri Dec 13 03:44:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376826, encodeId=bf6d3e68267b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Dec 11 14:28:14 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
    2019-12-11 1ddf0692m34(暂无匿称)

    学习了,谢谢分享

    0

相关资讯

Clin Transl Allergy:季节性过敏性鼻炎中鲁帕他定20毫克和10毫克的临床相关性影响

不同的临床试验表明了与安慰剂对比,在改善季节性过敏性鼻炎(SAR)症状方面鲁帕他定卓越的效果,但是还没有研究评估上述响应是具有临床意义的。研究是一个合并的分析,包括了7个随机、双盲、安慰剂对照SAR研究。研究共包括了1470名患者:其中332名为安慰剂治疗,662名为鲁帕他定10毫克治疗,476名为鲁帕他定20毫克治疗。研究发现,鲁帕他定与安慰剂相比,在治疗14天期间的T4NSS, T2OSS和T

Eur Respir J:生命早期暴露于空气污染与儿童哮喘、过敏性鼻炎和湿疹的发生率

由此可见,暴露于氧化性空气污染物(O3和NO2)而不是PM2.5与儿童患哮喘和湿疹的风险增加相关。这表明改善空气质量可能有助于预防儿童期和青春期的哮喘和其他过敏性疾病。

J Diet Suppl:饮食中补充鹌鹑蛋对过敏性鼻炎影响效果研究

之前的数据表明基于鹌鹑蛋的专利混合物对过敏原挑战诱导的过敏性鼻炎(AR)症状具有潜在的治疗作用。因此,有研究人员调查了相似的饮食补充对AR患者治疗的安全性和效果情况,其中包括了鹌鹑蛋的生物活性成分及锌矿物质。研究包括了77名成年患者,年龄在18-60岁,且具有轻度和间歇性的AR。研究是一个单臂和开放标签的试验。患者的响应通过2次的峰值鼻吸气流量(PNIF)测量(第1天/visit1和第7天/vis

Chest:居住在高海拔儿童过敏性鼻炎和阻塞性睡眠呼吸暂停研究

阻塞性睡眠呼吸暂停(OSA)影响了2-4%的儿童群体。之前的研究已经鉴定了过敏性鼻炎(AR)是睡眠呼吸障碍的一个风险因子,但是没有研究评估高海拔环境下上述的相关性情况。最近,有研究人员评估了是否高海拔居住儿童的AR的严重度与OSA的严重度相关。研究是一个代表性的研究,并在患有AR的儿童中进行。研究人员利用ESPRINT-15调查问卷和ARIA分类对AR严重度进行了评估,并利用多导睡眠图记录(PSG

Allergol Immunopathol (Madr):过敏性鼻炎患者中皮刺测试与血清特异性免疫球蛋白E相关性研究

美洲蟑螂是一种常见的过敏性鼻炎(AR)患者的气源性过敏原。皮刺测试(SPT)与美洲蟑螂特异性免疫球蛋白(slgE)之间的关系仍旧不确定。最近,有研究人员评估了SPT与美洲蟑螂slgE在AR患者中的相关性情况。研究是一个代表性的研究,AR患者的年龄在6-25岁,进行的时间为2013年9月到2014年10月。研究共包括了67名AR患者,平均年龄为15岁。研究发现,SPT和美洲蟑螂slgE分别在患者中的

Int Arch Allergy Immunol:过敏性鼻炎患者中舌下和皮下免疫治疗CD4+CD25+FoxP3调控T细胞和血清细胞因子变化研究

很少有研究直接比较皮下免疫治疗(SCIT)和舌下免疫治疗(SLIT)在免疫应答方面的情况。最近,有研究人员直接比较了SLIT和SCIT在对屋尘螨过敏的过敏性鼻炎患者中的临床效果和免疫响应情况。研究包括了67名中度到重度AR患者,他们患有或者不患有哮喘,年龄在5-55岁,并以2:2:1的比例随机分配到SLIT治疗组(n=27)、SCIT组(n=26)和安慰剂组(n=14)。研究发现,在1年的治疗后,

Baidu
map
Baidu
map
Baidu
map